Float Short %

24.14

Margin Of Safety %

-26

Put/Call OI Ratio

0.61

EPS Next Q Diff

-0.1

EPS Last/This Y

1.7

EPS This/Next Y

-3.15

Price

34.3

Target Price

41.89

Analyst Recom

Performance Q

18.57

Upside

-75.0%

Beta

1.08

Ticker: STOK

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	STOK	29.49	0.71	0.13	2724
2026-01-26	STOK	29.25	0.71	2.10	2730
2026-01-27	STOK	29.56	0.73	0.00	2785
2026-01-28	STOK	29.38	0.73	0.00	2796
2026-01-29	STOK	31.07	0.62	0.57	3072
2026-01-30	STOK	30.36	0.63	0.21	3091
2026-02-02	STOK	30.78	0.63	16.50	3099
2026-02-03	STOK	33.83	0.64	0.09	3134
2026-02-04	STOK	32.02	0.65	0.46	3115
2026-02-05	STOK	30.52	0.65	4.83	3138
2026-02-06	STOK	32.32	0.67	0.26	3145
2026-02-09	STOK	31.97	0.66	2.08	3153
2026-02-10	STOK	32.45	0.68	0.44	3178
2026-02-11	STOK	32.23	0.68	7.00	3185
2026-02-12	STOK	31.96	0.61	0.00	3406
2026-02-13	STOK	31.92	0.60	1.47	3409
2026-02-17	STOK	31.08	0.63	0.02	3455
2026-02-18	STOK	30.98	0.61	0.47	3503
2026-02-19	STOK	34.38	0.61	0.24	3523
2026-02-20	STOK	34.22	0.61	0.67	3481
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	STOK	29.51	-307.6	-	0.05
2026-01-26	STOK	29.28	-307.6	-	0.05
2026-01-27	STOK	29.55	-307.6	-	0.05
2026-01-28	STOK	29.36	-307.6	-	0.05
2026-01-29	STOK	31.08	-307.6	-	0.05
2026-01-30	STOK	30.36	-307.6	-	0.05
2026-02-02	STOK	30.80	-307.6	-	0.05
2026-02-03	STOK	33.84	-306.9	-	0.05
2026-02-04	STOK	32.01	-306.9	-	0.05
2026-02-05	STOK	30.49	-306.9	-	0.05
2026-02-06	STOK	32.39	-306.9	-	0.05
2026-02-09	STOK	31.99	-301.2	-	0.05
2026-02-10	STOK	32.45	-301.2	-	0.05
2026-02-11	STOK	32.22	-301.2	-	0.05
2026-02-12	STOK	31.95	-301.2	-	0.05
2026-02-13	STOK	31.82	-301.2	-	0.05
2026-02-17	STOK	31.13	-301.2	-	0.05
2026-02-18	STOK	30.99	-301.2	-	0.05
2026-02-19	STOK	34.42	-301.2	-	0.05
2026-02-20	STOK	34.30	-301.2	-	0.05
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	STOK	-3.16	4.23	23.15
2026-01-26	STOK	-3.16	4.25	23.15
2026-01-27	STOK	-3.16	4.25	23.15
2026-01-28	STOK	-3.16	4.25	24.07
2026-01-29	STOK	-3.16	4.25	24.07
2026-01-30	STOK	-3.16	4.25	24.07
2026-02-02	STOK	-3.16	4.65	24.07
2026-02-03	STOK	-3.16	4.65	24.07
2026-02-04	STOK	-3.16	4.65	24.07
2026-02-05	STOK	-3.16	4.65	24.07
2026-02-06	STOK	-3.12	4.65	24.07
2026-02-09	STOK	-3.12	4.29	24.07
2026-02-10	STOK	-3.12	4.29	24.07
2026-02-11	STOK	-3.12	4.29	24.14
2026-02-12	STOK	-3.12	4.29	24.14
2026-02-13	STOK	-3.12	4.29	24.14
2026-02-17	STOK	-3.00	4.95	24.14
2026-02-18	STOK	-3.00	4.95	24.14
2026-02-19	STOK	-3.00	4.95	24.14
2026-02-20	STOK	-3.00	4.95	24.14
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.65

Avg. EPS Est. Current Quarter

-0.72

Avg. EPS Est. Next Quarter

-0.75

Insider Transactions

-3

Institutional Transactions

4.95

Beta

1.08

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

25.46

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

46.5

Max Drawdown 5-Year %

-94.5

Target Price

41.89

P/E

51.96

Forward P/E

PEG

P/S

9.52

P/B

6.13

P/Free Cash Flow

37.4

EPS

0.66

Average EPS Est. Cur. Y

0.05

EPS Next Y. (Est.)

-3.11

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

19.73

Relative Volume

1.08

Return on Equity vs Sector %

-15.8

Return on Equity vs Industry %

1.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Stoke Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 128

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

stock quote shares STOK – Stoke Therapeutics, Inc. Stock Price stock today

news today STOK – Stoke Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch STOK – Stoke Therapeutics, Inc. yahoo finance google finance

stock history STOK – Stoke Therapeutics, Inc. invest stock market

stock prices STOK premarket after hours

ticker STOK fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: STOK

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y